These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19804365)

  • 1. Cancer Osaka thyroid (Cot) phosphorylates Polo-like kinase (PLK1) at Ser137 but not at Thr210.
    Wu B; Jiang P; Mu Y; Wilmouth RC
    Biol Chem; 2009 Dec; 390(12):1271-7. PubMed ID: 19804365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NIK and Cot cooperate to trigger NF-kappaB p65 phosphorylation.
    Wittwer T; Schmitz ML
    Biochem Biophys Res Commun; 2008 Jun; 371(2):294-7. PubMed ID: 18439422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purification and proteomic identification of putative upstream regulators of polo-like kinase-1 from mitotic cell extracts.
    Ji JH; Hwang HI; Lee HJ; Hyun SY; Kang HJ; Jang YJ
    FEBS Lett; 2010 Oct; 584(20):4299-305. PubMed ID: 20869364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique subcellular distribution of phosphorylated Plk1 (Ser137 and Thr210) in mouse oocytes during meiotic division and pPlk1(Ser137) involvement in spindle formation and REC8 cleavage.
    Du J; Cao Y; Wang Q; Zhang N; Liu X; Chen D; Liu X; Xu Q; Ma W
    Cell Cycle; 2015; 14(22):3566-79. PubMed ID: 26654596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
    Reindl W; Strebhardt K; Berg T
    Anal Biochem; 2008 Dec; 383(2):205-9. PubMed ID: 18793607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plk3 phosphorylates topoisomerase IIalpha at Thr(1342), a site that is not recognized by Plk1.
    Iida M; Matsuda M; Komatani H
    Biochem J; 2008 Apr; 411(1):27-32. PubMed ID: 18062778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization.
    García-Alvarez B; de Cárcer G; Ibañez S; Bragado-Nilsson E; Montoya G
    Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3107-12. PubMed ID: 17307877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands.
    Elling RA; Fucini RV; Romanowski MJ
    Acta Crystallogr D Biol Crystallogr; 2008 Sep; 64(Pt 9):909-18. PubMed ID: 18703838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of the catalytic domain of human polo-like kinase 1.
    Kothe M; Kohls D; Low S; Coli R; Cheng AC; Jacques SL; Johnson TL; Lewis C; Loh C; Nonomiya J; Sheils AL; Verdries KA; Wynn TA; Kuhn C; Ding YH
    Biochemistry; 2007 May; 46(20):5960-71. PubMed ID: 17461553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plk1 regulates liver tumor cell death by phosphorylation of TAp63.
    Komatsu S; Takenobu H; Ozaki T; Ando K; Koida N; Suenaga Y; Ichikawa T; Hishiki T; Chiba T; Iwama A; Yoshida H; Ohnuma N; Nakagawara A; Kamijo T
    Oncogene; 2009 Oct; 28(41):3631-41. PubMed ID: 19668228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choice of Plk1 docking partners during mitosis and cytokinesis is controlled by the activation state of Cdk1.
    Neef R; Gruneberg U; Kopajtich R; Li X; Nigg EA; Sillje H; Barr FA
    Nat Cell Biol; 2007 Apr; 9(4):436-44. PubMed ID: 17351640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylation by Cdk1 induces Plk1-mediated vimentin phosphorylation during mitosis.
    Yamaguchi T; Goto H; Yokoyama T; Silljé H; Hanisch A; Uldschmid A; Takai Y; Oguri T; Nigg EA; Inagaki M
    J Cell Biol; 2005 Nov; 171(3):431-6. PubMed ID: 16260496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P21-activated kinase is required for mitotic progression and regulates Plk1.
    Maroto B; Ye MB; von Lohneysen K; Schnelzer A; Knaus UG
    Oncogene; 2008 Aug; 27(36):4900-8. PubMed ID: 18427546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential phosphorylation of Nedd1 by Cdk1 and Plk1 is required for targeting of the gammaTuRC to the centrosome.
    Zhang X; Chen Q; Feng J; Hou J; Yang F; Liu J; Jiang Q; Zhang C
    J Cell Sci; 2009 Jul; 122(Pt 13):2240-51. PubMed ID: 19509060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation by polo-like kinase 1 induces the tumor-suppressing activity of FADD.
    Jang MS; Lee SJ; Kim CJ; Lee CW; Kim E
    Oncogene; 2011 Jan; 30(4):471-81. PubMed ID: 20890306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex formation of Plk1 and INCENP required for metaphase-anaphase transition.
    Goto H; Kiyono T; Tomono Y; Kawajiri A; Urano T; Furukawa K; Nigg EA; Inagaki M
    Nat Cell Biol; 2006 Feb; 8(2):180-7. PubMed ID: 16378098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polo-like kinase 1 creates the tension-sensing 3F3/2 phosphoepitope and modulates the association of spindle-checkpoint proteins at kinetochores.
    Ahonen LJ; Kallio MJ; Daum JR; Bolton M; Manke IA; Yaffe MB; Stukenberg PT; Gorbsky GJ
    Curr Biol; 2005 Jun; 15(12):1078-89. PubMed ID: 15964272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mutation within the catalytic domain of COT1 kinase confers changes in the presence of two COT1 isoforms and in Ser/Thr protein kinase and phosphatase activities in Neurospora crassa.
    Gorovits R; Propheta O; Kolot M; Dombradi V; Yarden O
    Fungal Genet Biol; 1999; 27(2-3):264-74. PubMed ID: 10441452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals.
    Guan R; Tapang P; Leverson JD; Albert D; Giranda VL; Luo Y
    Cancer Res; 2005 Apr; 65(7):2698-704. PubMed ID: 15805268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
    Johnson EF; Stewart KD; Woods KW; Giranda VL; Luo Y
    Biochemistry; 2007 Aug; 46(33):9551-63. PubMed ID: 17655330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.